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to elicit preference values for HCV-specific health states from general public par-
ticipants in Australia, Brazil, France, Italy, and Spain. METHODS: HCV health state 
descriptions were based on literature review and clinical expert feedback for the 
following: asymptomatic and symptomatic mild/moderate HCV, compensated cir-
rhosis, five decompensated cirrhosis states (hepatocellular carcinoma, ascites, acute 
and chronic variceal hemorrhage, and hepatic encephalopathy), and liver transplant 
(first year and subsequent years). These descriptions included key HRQoL impacts 
(activities, mood, stigma, cognition, and sleep) associated with each state, and were 
validated by members of the general public. Trained interviewers elicited time 
trade-off preference values (or, utilities) from a general public sample, quantifying 
preferences for each health state on a scale of 0 (dead) to 1 (full health). Mean (95% 
confidence interval) preferences were estimated for each country and adjusted for 
age and sex using beta and generalized linear models. RESULTS: Logical responses 
from 488 participants were included; approximately 50% were male. Mean ages 
ranged from 39.1 (Brazil) to 47.7 (Italy) years. Mean values for asymptomatic mild/
moderate HCV health states ranged from 0.90 (0.88-0.91; Australia) to 0.79 (0.76-
0.81; Brazil); for the acute variceal hemorrhage health state, mean values were 
0.27 (0.24-0.29; France) to 0.39 (0.39-0.42; Italy). Mean preferences for compensated 
cirrhosis ranged from 0.69 (0.33-0.72; Brazil) to 0.77 (0.75-0.79; Australia). Values 
were less than 0.70 for all decompensated cirrhosis states. Age- and sex-adjusted 
beta and generalized linear models showed similar results. CONCLUSIONS: This 
study provides estimates of the quality of life decrement associated with severe 
liver disease health states, from the general public perspective. This information 
is important for understanding the benefit of early treatment to delay disease pro-
gression in patients with HCV.
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OBJECTIVES: Standardized methods to measure symptoms and related patient-
reported outcomes (PRO) in Hospital-Acquired Bacterial Pneumonia (HABP) are 
limited. The purpose of this literature review was to identify signs, symptoms, and 
measurement tools associated with patients’ experience of HABP. The results will 
be used to inform the development of a valid PRO tool for HABP that is consistent 
with the FDA PRO Guidance. METHODS: To identify relevant literature, MEDLINE 
(1946 to 2014) and EMBASE (1988 to 2014) databases were searched individually 
and in combination using terms related to Hospital-Acquired Pneumonia (HAP), 
HABP, signs and symptoms, and patient-reported outcomes. RESULTS: The search 
identified 1384 abstracts. 225 were excluded as duplicates or for missing content. 
1145 abstracts were excluded based on pre-specified criteria. The remaining articles 
were scrutinized for eligibility, resulting in six that met the inclusion criteria. The 
most frequently cited signs and symptoms of HABP were fever, cough, purulent spu-
tum, dyspnea, rales, chest pain, and elevated respiratory rate. No PRO measures for 
assessing HABP signs and symptoms were identified in the literature. Current HABP 
clinical trials have not included end points that directly measure how a patient 
feels and functions. CONCLUSIONS: The HABP literature has historically focused 
on clinical outcomes to evaluate treatment efficacy and there is currently limited 
evidence assessing the impact of antibiotic therapies on symptomatology in HABP 
patients. Endpoints, such as clinical response, clinical cure, and time to event, are 
only indirect measures of treatment benefit and have not been validated. It is essen-
tial to develop reliable, well-defined and clinically relevant endpoints that measure 
tangible benefits for patients in clinical trials of antibacterial drugs in accordance 
with the FDA Guidance for PRO measures and HABP. This literature review is the first 
step in identifying concepts that will be explored further in qualitative interviews 
with HABP patients.
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OBJECTIVES: Pegylated-interferon/ribavirin (PR) is commonly used to treat HCV 
genotype 1 (G1) -infected patients, both as dual therapy or triple therapy, combined 
with a direct-acting antiviral (DAA). PR-based treatments are associated with high 
levels of toxicity and decreased QoL. Adding simeprevir as DAA to PR reduces dura-
tion of PR-therapy and increases significantly the proportion of patients reaching 
viral response (VR). The objective of this analysis was to explore the impact of dura-
tion of PR therapy and of having VR on the level of impairment of QOL and other 
patient-reported outcomes (PRO). METHODS: Longitudinal QoL/PRO outcomes were 
analyzed from three randomized clinical trials comparing PR+simeprevir with PR 
in treatment-naïve HCV-G1 patients: PILLAR (n= 316); QUEST-1 (n= 394) ; QUEST-2 
(n= 391). Early responders in the simeprevir arm were allowed to stop PR-therapy at 
24 weeks, instead of 48 week PR-therapy. A mixed-effects model was fitted, including 
age, gender, baseline fibrosis status, time, treatment interaction between time and 
treatment as covariates, and PR-therapy and viral response as binary time-varying 
covariates (viral load < /≥ 25 IU/ml). A model was fitted by trial for the EQ-5D valu-
ation index (VI) and visual analog scale (VAS), the Fatigue Symptom Severity scale 
(FSS) and the Center for Epidemiologic Studies Depression Scale (CES-D). RESULTS: 
Shortened PR-therapy positively impacted all PRO-endpoints consistently across all 
studies (p-values ranging between < 0.0001 and 0.025). The estimated mean for the 
positive impact on EQ5D-VI were 0.08 (p= 0.0001), 0.05 (p= 0.025) and 0.08 (p= 0.0005) 
this population. Results also suggest that the knowledge gap is greater among males 
than females. This in mind, PPPP includes culturally sensitive elements such as a 
skit developed by community members and small group discussions to engage the 
population in conversations about pneumonia.
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OBJECTIVES: The purpose of this study was to develop a patient-reported out-
come (PRO) instrument to assess Acute Bacterial Skin and Skin Structure Infection 
(ABSSSI) symptoms in patients in clinical trials of antibacterial drugs, consistent 
with FDA PRO Guidance. METHODS: A comprehensive review of the literature and 
interviews with nine US and European clinical experts informed the development 
of a concept elicitation (CE) interview guide, and a hypothetical conceptual frame-
work and disease model exploring patients’ experience with symptoms of ABSSSI. 
CE was based on telephone interviews with 34 patients, after which saturation 
of emergent concepts was reached. Items and response options were generated 
based on the qualitative data and a draft instrument was prepared with input and 
review from an international project team of academic and industry antibacte-
rial experts. Subsequently, cognitive debriefing interviews were conducted with 15 
ABSSSI patients and 3 clinical experts to assess item readability, relevance, com-
prehensiveness, and content validity. Items were edited based on feedback from 
the patients. RESULTS: CE subtypes were evaluated and consisted of 13 (38.2%) 
patients with major abscess, 12 (35.3%) with wound infection, and 9 (26.5%) with 
cellulitis. In terms of severity, the majority (79.4%) of infections were rated as moder-
ate by clinicians. The mean age of patients was 38.8 years; 64.7% male. Symptoms 
were common across all ABSSSI subtypes and supported the saturation of con-
cepts. Items were generated for the PRO Instrument using patient terminology. 
Subsequent cognitive debriefing with patients demonstrated that the items were 
understandable, relevant, and interpreted as intended. CONCLUSIONS: SKINFECT is 
a PRO instrument developed to evaluate ABSSSI patient symptoms and functioning 
in clinical studies with documented evidence of content validity. Qualitative data 
from patients and input from experts formed the basis of the SKINFECT’s structure 
and item pool, and it is now ready for psychometric reliability and validity testing.
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OBJECTIVES: There is a paucity of evidence regarding a well-defined, reliable, and 
feasible method for measuring efficacy outcomes from a patient perspective in 
Community-Acquired Bacterial Pneumonia (CABP) trials. Most CABP studies eval-
uate treatment efficacy on the basis of clinical outcomes; however, there is no 
patient-reported outcome (PRO) to capture additional symptoms of how patients 
feel, function, or survive. The goal of this study was to explore CABP symptoms as 
reported by patients, and to develop a draft PRO instrument designed to compre-
hensively assess these symptoms. METHODS: Concept elicitation was conducted by 
telephone interviews with patients within 10 days of CABP diagnosis. Data was ana-
lyzed using an iterative process to identify themes and concepts and was recorded 
in a saturation grid. Saturation was monitored according to the FDA PRO guidance. 
Using this qualitative data, a draft PRO instrument was prepared. Cognitive debrief-
ing interviews were conducted to assess item readability, relevance, comprehen-
siveness, and content validity. RESULTS: Twenty patients participated in concept 
elicitation interviews. Mean age of the patients was 59.5 years (SD = 18.8, range: 
29-90); 45% were female. The most common symptoms reported included a lack of 
energy or tiredness (n= 18), cough (n= 16), and shortness of breath (n= 16). Nearly 
half the patients also reported fever, chest pain and general aches/pain as well as 
significant impacts on their social (n= 10) and physical functioning (n= 17) related 
to the skin infection. Subsequent cognitive debriefing in 9 patients and 3 clinical 
experts demonstrated that the items were understandable, relevant, and interpreted 
as intended. CONCLUSIONS: Qualitative data from patients and input from experts 
formed the basis of the CABP PRO structure and item pool. These patient-reported 
CABP symptoms were shown to demonstrate content saturation and concept valid-
ity and provide unique information important for both comprehensive evaluation 
of individuals with CABP and evaluation of new antibacterial treatments.
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OBJECTIVES: Limited country-specific data exist on health-related quality-of-life 
(HRQoL) impacts of hepatitis C virus (HCV) infection. The aim of this study was 
